700.38MMarket Cap-8244P/E (TTM)
3.770High3.695Low378.49KVolume3.750Open3.750Pre Close1.41MTurnover0.28%Turnover RatioLossP/E (Static)188.78MShares3.98052wk High5.72P/B502.91MFloat Cap1.69052wk Low--Dividend TTM135.56MShs Float31.480Historical High--Div YieldTTM2.00%Amplitude0.821Historical Low3.718Avg Price1Lot Size
Arbutus Biopharma Stock Forum
Arbutus Biopharma Corp: Prioritizing Imdusiran Phase 2B Clinical Development. Also planning 40% reduction in workforce
Based on preliminary end-of-treatment data, Arbutus said that the therapy resulted in maintenance of lower hepatitis B surface antigen levels during the post-treatment follow-up period.
...
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Arbutus Biopharma (Nasdaq: ABUS) has announced promising new data presented at the European Association for the Study of the Liver (EASL) Congress regarding its RNAi therapeutic, Imdusiran, combined with the T-cell stimulating immunotherapeutic VTP-300. The Phase 2a trial showed significant reductions in Hepatitis B surface antigen (HBsAg) levels. At 24-weeks ...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
In reaction to earnings/guidance:
• $Super Micro Computer (SMCI.US)$ +18%, $Nokia Oyj (NOK.US)$ +7.7%, $Danaher (DHR.US)$ +6.3%, $RLI Corp (RLI.US)$ +5%, $CSX Corp (CSX.US)$ +4.3%, $Las Vegas Sands (LVS.US)$ +4.2%, $Alcoa (AA.US)$ +3.4%(also authorizes new $500 mln share repurchase program)
• $Steel Dynamics (STLD.US)$ +2.8%, $Herc Holdings (HRI.US)$ +2.6%, $Tesla (TSLA.US)$ +2.5%, $Philip Morris International (PM.US)$ +2.5%, $F.N.B. Corp (FNB.US)$ ...
No comment yet